Form 4: IGM Biosciences Executive Lisa Decker Sells Shares to Cover Tax Obligations

Lisa Decker, Chief Business Officer of IGM Biosciences, sold 925 shares of common stock on September 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On September 13, 2024, Lisa Decker, the Chief Business Officer of IGM Biosciences, sold 925 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $11.5388, with individual trades ranging from $11.20 to $11.795.
• Following the transaction, Decker directly owns 79,104 shares of IGM Biosciences common stock.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

This is a routine Form 4 filing related to an executive's stock sale to cover tax obligations, a common practice in publicly traded companies. It doesn't necessarily indicate a change in the executive's confidence in the company.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common occurrence across publicly traded companies.
• Similar transactions are regularly reported by executives at companies like Amgen, Regeneron, and Gilead Sciences.
• The size of the sale (925 shares) is relatively small compared to the total holdings (79,104 shares), suggesting it's primarily for tax purposes.

Stakeholder Impact

• The stock sale is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors, as it is a routine transaction.

Key Dates